Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment

Abstract

Metabolic syndrome is a serious risk factor for acute and chronic cerebrovascular disease, which are a leading cause of disabling conditions. The association of proatherogenic effects of the main components of metabolic syndrome--hyperinsulinemia, arterial hypertension, dyslipidemia and obesity--leads to prominent haemorheological and hemostasis changes, which in turn play a pivotal role in the initiation, course and outcome of cerebrovascular pathology. Metabolic syndrome also influences the efficacy of the main pathogenetic therapy of cerebrovascular diseases--antithrombotic therapy. Thus, primary and secondary prevention of cerebrovascular disease in patients with metabolic syndrome should include haemangiocorrective, antithrombotic, antioxidant and endothelium-protective treatment, as well as therapy of the main components of metabolic syndrome.

Anxiety disorders in clinical practice - a modern view on the problem of therapy

“…Мексидол ® обладает высоким профилем безопасности: в исследованиях профиль безопасности сравним с плацебо. Самое главное условие для максимального раскрытия терапевтического потенциала -последовательная длительная терапия препаратом Мексидол ® по 6 мл в/в капельно на физиологическом растворе 2 недели с последующим переходом на таблетированную форму Мексидол ФОРТЕ 250 по 1 таблетке 250 мг 3 раза в день 2 месяца [35,39] с повторением профилактических курсов 2 раза в год.…”